A Phase 2-3, 6-12 Month, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Subjects With Mild to Moderate Alzheimer's Disease Who Are APOE4(-).

Trial Profile

A Phase 2-3, 6-12 Month, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Subjects With Mild to Moderate Alzheimer's Disease Who Are APOE4(-).

Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 03 Dec 2012

At a glance

  • Drugs AC 1204 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms ALERT
  • Most Recent Events

    • 03 Dec 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 08 Jun 2011 Planned end date changed from 1 Jun 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 08 Jun 2011 Planned initiation date changed from 1 Jun 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top